| Name | Title | Contact Details |
|---|
EPOCH offers a 401(k) Retirement Savings Plan, with a variety of 25 fund options ranging from low to high risk, to choose from.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
PurposeCare is an integrated platform company that coordinates care in the community with a focus on individuals who are dually eligible for Medicaid and Medicare.
The Middle Peninsula Northern Neck Community Services Board is a public, nonprofit organization providing services to meet the needs of individuals and their families who have problems associated with mental health, intellectual disabilities, substance abuse, and developmental disabilities. Services are provided to residents in the Middle Peninsula and Northern Neck, VA. This area includes the counties of Westmoreland, Richmond, Essex, Northumberland, Lancaster, Gloucester, Mathews, Middlesex King & Queen and King William. It also includes the Town of Colonial Beach and West Point.
Postgraduate Institute for Medicine is a Englewood, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.